A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.